MASSACHUSETTS
-
Liberty All-Star® Growth Fund, Inc. Declares Distribution
BOSTON, April 11, 2022 /PRNewswire/ -- The Board of Directors of Liberty All-Star Growth Fund, Inc. (NYSE: ASG) has declared a distribution of $0.14 per share payable on June 6, 2022 to shareholders o…
-
Jobcase Strengthens Engineering Leadership while Further Investing in Workforce Data Expertise
CTO, Paw Andersen joins team as Tony Deigh moves into Chief Data Officer role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Jobcase, an online community dedicated to empowering and advocating for w…
-
Rockwell Medical Expands Partnership with DaVita
$7.5M initial equity investment in Rockwell Amended and expanded supply agreement Strengthens Rockwell's financial position, laying groundwork for improved concentrate business WIXOM, Mich., April 11,…
-
LLumin Accepted into Mitsubishi Electric e-F@ctory Alliance Partner Program
SPRINGFIELD, Mass., April 11, 2022 /PRNewswire/ -- LLumin, a premier CMMS (computerized maintenance management system) provider, announces its participation in the e-F@ctory Alliance Partner Program b…
-
NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS
Study conducted under FDA cleared protocol in parallel with international Phase IIb trial expected to commence in Q2 2022 CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.…
-
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
Extends Core Intellectual Property coverage for treatment of lung cancer as well as esophageal cancer. HOLLISTON, Mass., April 11, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the…
-
Stealth BioTherapeutics Announces $8.5 Million in Equity Financings
BOSTON, April 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization o…
-
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Data demonstrate significantly greater anti-tumor activity of cytoTIL15 therapy in vivo compared to conventional TIL + IL2 therapy CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Obsidian Therapeutic…
-
FORM Named A Top 10 Audit Management Company of 2022 For Mobile Inspection Software
Insights Success Evaluated Global Software Providers Improving Compliance Outcomes for Environment, Health, Safety, and Operational Business Processes QUINCY, Mass., April 11, 2022 /PRNewswire/ -- FOR…
-
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
Curis voluntarily paused enrollment in this study earlier LEXINGTON, Mass., April 11, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative…
-
Babson College Announces Naming of the Bertarelli Institute for Family Entrepreneurship
Institute Creates Global Family Entrepreneurship Network Empowering Enterprising Families to Create Economic Value and Social Impact Built Upon Foundation of Stronger Family Relationships WELLESLEY, M…
-
Tive Raises $54M in Series B Funding Led by AXA Venture Partners
300%+ revenue growth, 200+ new global customers, and hired 100+ employees in 2021, six new investors in the B round, and thousands of shipments saved from delays, spoilage, damage or loss. BOSTON, Apr…
-
Continuous Glucose Monitors Drives Growth of the Diabetes Technology Market, Finds IDTechEx
BOSTON, April 11, 2022 /PRNewswire/ -- IDTechEx has recently released "Diabetes Management Technologies 2022-2032: Markets, Players, and Forecasts", a market research report exploring the technical, r…
-
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
WALTHAM, Mass., April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicin…
-
Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna
Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced i…
-
Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming
CAMBRIDGE, Mass., April 10, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, toda…
-
HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022
In Vitro and In Vivo Data for CBL-B Inhibitor Demonstrated Differentiated Immune Enhancing Activity BOSTON, April 8, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering…
-
Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022
NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and kinase-domain resistance mutations, as well as in a ROS1-driven model of glioblastoma NVL-655 demonstrated different…
-
Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022
OTX-2002 suppresses c-Myc gene expression resulting in a loss of cancer cell viability in vitro and reduces tumor growth in in vivo xenograft modelsData support the potential of the OMEGA Epigenomic P…
-
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
NORWOOD, Mass., April 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CR…